James G. Christensen
Memorial Sloan Kettering Cancer Center(US)Bristol-Myers Squibb (Germany)(DE)Kettering University(US)Bristol-Myers Squibb (United States)(US)Mirati Therapeutics (United States)(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Colorectal Cancer Treatments and Studies, HER2/EGFR in Cancer Research, Liver physiology and pathology, Cancer-related gene regulation
Most-Cited Works
- → Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer(2010)4,491 cited
- → MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling(2007)4,440 cited
- → Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors(2011)3,533 cited
- → Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer(2014)1,981 cited
- In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.(2003)
- → Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis(2009)1,697 cited